You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
The firm's Q-plasia OncoReader Breast is the first in its line of products for different cancers, including skin, lung, and ovarian cancer.
On the back of a recently announced $3 million in funding, the firm has begun marketing its Urodiag kit to urologists throughout Europe.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
The $1 billion, part of a total of $4 billion in funding, will go toward detecting, diagnosing, tracing, monitoring, and mitigating COVID-19 infections.
The pilot program is intended to increase consistency and predictability when determining conformity with consensus standards and test methods.